Targeted attack on stomach cancer halted before it began
NCT ID NCT06967987
Summary
This study aimed to see if adding a new targeted drug, bemarituzumab, to standard chemotherapy could better treat certain stomach and gastroesophageal junction cancers before and after surgery. It was designed for patients whose cancer cells had high levels of a specific protein called FGFR2b. The main goal was to see if this combination could completely eliminate the cancer cells in the surgically removed tissue. However, the trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC AND GASTRO-OESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Brest
Brest, 29609, France
-
CHU de Poitiers
Poitiers, 86021, France
-
CHU de Rennes
Rennes, 35000, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Gustave Roussy
Villejuif, 94805, France
-
Institut Bergonié
Bordeaux, 33000, France
-
Institut Paoli Calmette
Marseille, 13273, France
-
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, 54519, France
-
Institut de Cancérologie de l'Ouest
Angers, 49055, France
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, 44805, France
Conditions
Explore the condition pages connected to this study.